0000950170-24-003647.txt : 20240110
0000950170-24-003647.hdr.sgml : 20240110
20240110162938
ACCESSION NUMBER: 0000950170-24-003647
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240109
FILED AS OF DATE: 20240110
DATE AS OF CHANGE: 20240110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dulac Edward J III
CENTRAL INDEX KEY: 0001821530
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 24526904
MAIL ADDRESS:
STREET 1: FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT STE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 651311552
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 12278 SCRIPPS SUMMIT DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92131
4
1
ownership.xml
4
X0508
4
2024-01-09
0001434316
FATE THERAPEUTICS INC
FATE
0001821530
Dulac Edward J III
C/O FATE THERAPEUTICS, INC.
12278 SCRIPPS SUMMIT DRIVE
SAN DIEGO
CA
92131
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-01-09
4
S
false
7028
4.37
D
105775
D
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021 and 8,326 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Represents the weighted average sale price of the shares sold ranging from $4.02 to $4.51 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
/s/ Cindy Tahl, as Attorney-in-Fact
2024-01-10